ADAPTIVE BIOTECHNOLOGIES CORP

Company Overview

Adaptive Biotechnologies is a Seattle‑based biotechnology company that commercializes immunosequencing and computational immune‑repertoire products. Its business is organized into an MRD commercial franchise anchored by clonoSEQ — an FDA‑authorized NGS assay for minimal residual disease (MRD) with broad Medicare and private‑payer coverage — and an Immune Medicine discovery business focused on TCR/BCR‑based drug discovery in oncology and autoimmune disease (notably a Genentech collaboration). The company reported 2024 revenue of $179.0M (MRD $145.5M, test volume 76,105, +35% YoY), holds a large proprietary dataset and patent estate, and operates a CLIA/CAP/ISO‑certified Seattle lab while remaining exposed to reimbursement, supplier concentration and collaboration‑revenue timing risks.

Executive Compensation Practices

Compensation at Adaptive is likely driven by a mix of commercial adoption metrics (clonoSEQ test volume, MRD revenue and reimbursement outcomes), milestone and collaboration payments from partners (e.g., Genentech), and longer‑term R&D progress in the Immune Medicine pipeline. As a biotech, the company probably emphasizes equity‑based pay (options/RSUs and milestone‑linked awards) to conserve cash—particularly given multi‑year R&D timelines and an improving but still negative adjusted EBITDA—and uses bonuses or performance shares tied to revenue milestones, regulatory/coverage wins, and partner milestone recognitions. Recent cost realignments and restructurings that materially reduced operating expenses suggest compensation design may include scorecards tied to cost control and cash‑runway metrics, while any concession to short‑term cash constraints could increase reliance on longer‑dated equity or milestone pay.

Insider Trading Considerations

Insider trading activity should be monitored around high‑information events that materially affect revenue recognition and outlook: Medicare/coverage announcements, per‑test or episode pricing changes, biopharma milestone recognitions, clinical trial sample delivery timing, Genentech program updates, quarterly results and any financing draws under the Revenue Interest Purchase Agreement (net proceeds $124.4M received to date). Given the company’s sensitivity to reimbursement and milestone timing, insider purchases would be a relatively strong signal of confidence, whereas sizable sales may reflect option exercises, tax needs, or concerns about dilution/cash runway (cash was $256M at year‑end 2024 and $222M at 6/30/25). Expect standard biotech trading controls—blackout windows around material events and frequent use of 10b5‑1 plans—and watch Form 4 filings for patterns of sales following equity vesting or financing announcements.